Phreesia Stock Price, News & Analysis

Phreesia's Vice President of Product Management, Sally Thayer, has been named to The Software Report's Top 50 Women Leaders in Software of 2024. This marks the seventh consecutive year a female leader from Phreesia has received this recognition. In her role, Thayer oversees patient engagement applications and manages multiple product teams developing software solutions for healthcare organizations.

With over 20 years of healthcare technology experience, Thayer leads teams responsible for patient registration, communication, clinical documentation, and user experience. Under her leadership, Phreesia enabled approximately 150 million patient visits in 2023, representing more than 1 in 10 visits across the U.S. The company, founded in 2005, specializes in patient intake, outreach, and activation solutions.

Phreesia (NYSE: PHR) has announced it will release its fiscal fourth quarter and fiscal year 2025 financial results after market trading on Wednesday, March 12, 2025. The company will publish a press release and quarterly stakeholder letter on its investor website at ir.phreesia.com, followed by a conference call at 5PM Eastern Time.

Investors can participate in the conference call by dialing (800) 715-9871 (US) or (646) 307-1963 (international) using conference code 7404611. A replay will be available via webcast for approximately 90 days. Founded in 2005, Phreesia is a patient activation platform that facilitated approximately 150 million patient visits in 2023, representing more than 1 in 10 healthcare visits across the U.S.

Phreesia (NYSE: PHR) reported its Q3 FY2025 financial results with total revenue of $106.8 million, up 17% year-over-year. The company's average healthcare services clients (AHSCs) increased 15% to 4,237. Net loss improved to $14.4 million from $31.9 million in the prior year, while Adjusted EBITDA turned positive at $9.8 million compared to negative $6.6 million.

The company narrowed its FY2025 revenue guidance to $418-420 million (17-18% growth) and raised Adjusted EBITDA outlook to $34-36 million. For FY2026, Phreesia projects revenue of $472-482 million and Adjusted EBITDA of $78-88 million, with AHSCs expected to reach approximately 4,500.

Phreesia has been named one of the 'Top 100 Software Companies of 2024' by The Software Report for the third consecutive year, ranking 11th on the list, up four positions from 2023. The selection criteria included product functionality, customer satisfaction, corporate reputation, innovative capabilities, organizational depth, ESG involvement, and long-term viability.

As a leader in patient intake, outreach and activation, Phreesia facilitated approximately 150 million patient visits in 2023, representing more than 1 in 10 healthcare visits across the U.S. The company provides patient-driven digital solutions for intake, outreach, and education to enhance patient experience and improve healthcare outcomes.

Phreesia (NYSE: PHR) has announced it will release its fiscal third quarter 2025 financial results after market close on Monday, December 9, 2024. The company will host a conference call at 5PM Eastern Time on the same day to discuss the results. Founded in 2005, Phreesia is a patient activation platform that facilitated approximately 150 million patient visits in 2023, representing more than 1 in 10 healthcare visits across the U.S. The company provides digital solutions for patient intake, outreach, and education to enhance patient experience and healthcare outcomes.

Phreesia has achieved Oracle Validated Integration with Oracle Health Electronic Health Record (EHR) Expertise for its patient intake platform integration. The validation confirms the integration's functionality and performance, enabling healthcare organizations to enhance patient experience and operational efficiency. Phreesia's research shows that Oracle customers using their platform have experienced significant improvements, including a 25% increase in payment collections, 77% copay collection at time of service, and staff saving over five minutes per visit with 87% of patients using self-check-in.

Phreesia, a leader in patient activation, has joined the Network Advertising Initiative (NAI), a non-profit organization dedicated to responsible data collection and use in digital advertising. This move demonstrates Phreesia's commitment to consumer data privacy and industry-leading privacy practices.

As an NAI member, Phreesia will:

• Promote consumer-centric privacy practices in healthcare
• Take a leadership role in shaping the national conversation around data privacy
• Advocate for national policies that allow beneficial use of healthcare data while preserving consumer privacy

Phreesia's platform focuses on personalized health content built on principles of privacy and consent. The company's research shows that consumers value receiving relevant health information, with over 80% of surveyed individuals appreciating personalized content about medications or therapies related to their health conditions.

Phreesia, a leader in patient intake, has partnered with the Ad Council to deliver three mental health awareness campaigns to patients and caregivers. The campaigns have reached over 430,000 individuals, focusing on youth, adult, and adolescent mental health. Key findings show that most viewers plan to discuss mental health with doctors, family, or friends, and over half are likely to seek additional information.

The campaigns include:

• 'Seize the Awkward': Targeting young adults 18-24, delivering 255,000 messages
• 'Sound It Out': Aimed at parents of middle schoolers and teens, with 60,000 messages
• 'Love, Your Mind': Focused on Black and Hispanic men, delivering 117,000 messages

Results indicate high engagement, with many recipients requesting resources and expressing intentions to discuss mental health with healthcare providers or loved ones. The partnership aims to normalize mental health discussions and provide tools for important conversations.

Phreesia, a leader in patient intake and activation, has renewed its contract with the CMS Innovation Center (CMMI) for the use of the Patient Activation Measure® (PAM) through 2029. The PAM assesses patients' knowledge, skills, and confidence in managing their healthcare. This renewal follows the success of the Kidney Care Choices (KCC) Model, which aims to improve care for Medicare beneficiaries with chronic kidney disease.

The first annual evaluation of the KCC model revealed significant improvements, including:

• An average 8.8-point increase in PAM scores
• A 20% increase in home dialysis
• A 16% increase in optimal ESRD starts
• A 15% increase in patients on the transplant waitlist

These results demonstrate the effectiveness of patient activation in improving healthcare outcomes and reducing costs. Phreesia's continued partnership with CMMI may lead to expanded use of PAM in additional healthcare models and settings.